Bristol-Myers Squibb: BMS' Camzyos flops in Phase III non-obstructive hypertrophic cardiomyopathy trial
BMS could soon face competition in the HCM space as Cytokinetics awaits a marketing application decision from the FDA for aficamten. The post BMS' Camzyos flops in Phase III non-obstructive hypertrophic cardiomyopathy trial appeared first on Clinical Trials Arena.
Read full article »
Bristol Myers Squibb is a New Jersey-based biopharmaceutical company that discovers, develops and commercializes medicines for patients with serious diseases.
Read more